FOR RESEARCH USE ONLY
Early human researchMelanocortin research

Melanotan II

Synthetic melanocortin receptor agonist researched for melanogenesis, photoprotection and appetite modulation.

01MC1R pigmentation02MC3R / MC4R03Melanocortin safety
Molecular signature / melanotan-ii
Structural identity

Cyclic heptapeptide, non-selective melanocortin receptor agonist

Also known as

MT-II · Melanotan-2 · Cyclic α-MSH analogue

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a non-selective melanocortin receptor agonist studied primarily for stimulating melanin production (melanogenesis) in skin research models, with additional research interest in appetite regulation, energy homeostasis and sexual-function pathways.

The research question

Melanotan II activates several melanocortin receptors, so pigmentation is only one part of its pharmacology. Appetite, autonomic effects, sexual-function pathways and changes in existing naevi all belong in a complete research assessment.

Section 02

Mechanism & research themes

Agonises melanocortin receptors MC1R, MC3R, MC4R and MC5R. MC1R activation on melanocytes upregulates tyrosinase activity and eumelanin synthesis, increasing skin pigmentation. MC4R signalling in the hypothalamus mediates observed effects on appetite and energy expenditure, while MC3R/MC4R activity is linked to effects on sexual arousal pathways in research models.

01

Stimulated eumelanin production and skin pigmentation in research models

02

Studied for photoprotective effects against UV-induced skin damage

03

MC4R-mediated appetite suppression observed in metabolic research

04

Research interest in sexual-function and arousal pathways

05

Potential applications in erythropoietic protoporphyria and vitiligo research (analogue class)

06

Long-lasting pigmentation effects relative to dosing frequency

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Small human studies establish biological activity, not a favourable long-term risk profile. Non-selective receptor activity and changes in pigmented lesions remain important safety questions.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 250–500mcg subcutaneously once daily, often starting at 100–250mcg to assess tolerability before titrating upward. Loading phases typically run 2–4 weeks, followed by maintenance dosing of 500mcg–1mg one to two times weekly. Administering in the evening is common in research to minimise transient nausea.

Reported persistence

Plasma half-life approximately 33 minutes; downstream melanogenic effects persist for days to weeks via sustained melanocyte stimulation.

Calculator starting point

0.25 mg per reference dose

7 doses per week · 4-week cycle

2 mL default reconstitution volume

Start 100–250 mcg/day SC to assess tolerance, titrate to 250–500 mcg/day; maintenance 500 mcg–1 mg 1–2×/week. Evening dosing common to minimise nausea.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Melanotan II
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 10mg vial with 2mL bacteriostatic water for a 5mg/mL working concentration (500mcg per 0.1mL / 10 units on a U-100 syringe). Inject water slowly down the side of the vial and swirl gently — do not shake.

Storage reference

Lyophilised: refrigerate at 2–8°C (stable up to approximately 24 months); protect from light. Reconstituted: store at 2–8°C, protect from light, and use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Transient nausea, facial flushing and appetite suppression are the most commonly reported acute effects, typically dose-dependent.

L2

Darkening of existing moles and new nevi appearance have been reported — dermatological monitoring is advised in research settings.

L3

Non-selective receptor activity means off-target melanocortin effects are possible; not approved for human use.

L4

Spontaneous erections reported in male research subjects at higher doses (MC4R-mediated).

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only